PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis - PubMed (original) (raw)

. 2008 Mar 18;105(11):4277-82.

doi: 10.1073/pnas.0708647105. Epub 2008 Mar 12.

Joey Liu, Fen Yin, Alan R Collins, Christopher J Lyon, Chih-Hao Lee, Annette R Atkins, Michael Downes, Grant D Barish, Ronald M Evans, Willa A Hsueh, Rajendra K Tangirala

Affiliations

PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis

Yasunori Takata et al. Proc Natl Acad Sci U S A. 2008.

Abstract

Activation of the nuclear hormone receptor peroxisome proliferator-activated receptor delta (PPARdelta) has been shown to improve insulin resistance, adiposity, and plasma HDL levels. However, its antiatherogenic role remains controversial. Here we report atheroprotective effects of PPARdelta activation in a model of angiotensin II (AngII)-accelerated atherosclerosis, characterized by increased vascular inflammation related to repression of an antiinflammatory corepressor, B cell lymphoma-6 (Bcl-6), and the regulators of G protein-coupled signaling (RGS) proteins RGS4 and RGS5. In this model, administration of the PPARdelta agonist GW0742 (1 or 10 mg/kg) substantially attenuated AngII-accelerated atherosclerosis without altering blood pressure and increased vascular expression of Bcl-6, RGS4, and RGS5, which was associated with suppression of inflammatory and atherogenic gene expression in the artery. In vitro studies demonstrated similar changes in AngII-treated macrophages: PPARdelta activation increased both total and free Bcl-6 levels and inhibited AngII activation of MAP kinases, p38, and ERK1/2. These studies uncover crucial proinflammatory mechanisms of AngII and highlight actions of PPARdelta activation to inhibit AngII signaling, which is atheroprotective.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.

Fig. 1.

PPARδ activation attenuates AngII-accelerated atherosclerosis. Male LDLR−/− mice were treated with HF/PBS, HF/AngII, or HF/AngII/GW0742 (1 mpk or 10 mpk) for 4 weeks. (A) Aortic PPARδ mRNA expression after 2 and 4 weeks of HF/AngII treatment. Data are mean ± SD (n = 12 per group). *, P < 0.01 vs. HF. (B) Localization of aorta PPARδ protein expression by immunohistochemistry. PPARδ protein expression localized predominantly to macrophage-rich areas (CD68-positive intimal layer) and intimal vascular smooth muscle cells in lesions. (Magnification: ×40.) (C) Representative Sudan IV-stained aortas. (D) Quantification of en face atherosclerotic lesion coverage. Data are mean ± SD (n = 8 per group). *, P < 0.01 vs. HF/AngII by ANOVA.

Fig. 2.

Fig. 2.

PPARδ activation suppresses AngII-induced vascular inflammation macrophage infiltration. (A) Macrophage abundance (Mac-2 antibody stain) in aortic root lesions. (B) Quantitative analysis of Mac-2-positive area in the aortic root lesions. (C) RT-PCR analysis of aortic expression of two macrophage markers (CD68 and Mac-2). RNA from the whole aortas was analyzed by qRT-PCR and normalized to GAPDH expression. (D) PPARδ agonist inhibits AngII-induced vascular inflammation. RNA levels in the aorta were analyzed by using qRT-PCR and normalized to GAPDH. Data are mean ± SD (n = 12 per group). *, P < 0.01 vs. HF/AngII by ANOVA.

Fig. 3.

Fig. 3.

AngII suppresses Bcl-6 expression in the aorta and macrophage. RNA isolated from whole aorta (A) and peritoneal macrophages (B) was analyzed by qRT-PCR. Bcl-6 expression was normalized to GAPDH. Data are mean ± SD (n = 6–10 per group). *, P < 0.01 vs. HF/AngII by ANOVA. (C) AngII increases and PPARδ ligand decreases macrophage PPARδ protein expression. (D and E) Bcl-6 protein expression and PPARδ:Bcl-6 interaction in macrophages in response to AngII and/or GW0742. Bcl-6:PPARδ interaction was analyzed by Western blot analyses of total and PPARδ-bound Bcl-6 in macrophage nuclear proteins after pull-down assays. (F and G) MCP-1 and OPN mRNA levels in peritoneal macrophages treated with AngII and/or GW0742. Data are mean ± SD (n = 5 per group). *, P < 0.01 vs. HF/AngII by ANOVA.

Fig. 4.

Fig. 4.

PPARδ activation inhibits AngII-induced phosphorylation of MAP kinases. Mouse peritoneal macrophages stimulated with AngII in the presence or absence of GW0742 were analyzed by Western blot for MAP kinase activation. Activation of p38 (A) and ERK1/2 (B) was measured by the levels of phosphorylated p38 (pp38) and ERK1/2 (pERK1/2) normalized to total p38 and ERK1/2. n = 3 per group. *, P < 0.05 vs. AngII by ANOVA.

Fig. 5.

Fig. 5.

PPARδ activation inhibits AngII-mediated G protein signaling and suppression of RGS4 and RGS5 in macrophages. AngII infusion inhibits aorta RGS4 (A) and RGS5 (B) expression, and this effect is reversed by GW0742. Aorta RNA was analyzed by qRT-PCR, and RGS4 and RGS5 mRNA levels were normalized to GAPDH. Data are mean ± SD (n = 5 per group). *, P < 0.001 vs. HF/PBS; **, P < 0.05 vs. HF/AngII (by ANOVA).

Similar articles

Cited by

References

    1. Halkin A, Keren G. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med. 2002;112:126–134. - PubMed
    1. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation. 2001;103:448–454. - PubMed
    1. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605–1612. - PMC - PubMed
    1. Dol F, et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2001;38:395–405. - PubMed
    1. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21:20–27. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources